Arcutis Biotherapeutics, Inc. (ARQT)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 81.5M | 99.2M | 129.5M | 105.4M |
| Gross Profit | 74.0M | 90.5M | 117.8M | 95.6M |
| Operating Income | -14.6M | 8.5M | 18.4M | -9.1M |
| Net Income | -15.9M | 7.4M | 17.4M | -11.3M |
| Diluted EPS | $-0.13 | $0.06 | $0.13 | $-0.09 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.7M | 59.6M | 196.5M | 376.1M |
| Gross Profit | 2.9M | 54.6M | 177.4M | 339.4M |
| Operating Income | -301.6M | -241.1M | -128.4M | -12.2M |
| Net Income | -311.5M | -262.1M | -140.0M | -16.1M |
| Diluted EPS | $-5.66 | $-3.78 | $-1.16 | $-0.13 |